Related references
Note: Only part of the references are listed.FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides
Annemieke Aartsma-Rus
NUCLEIC ACID THERAPEUTICS (2017)
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Catherine L. Bladen et al.
HUMAN MUTATION (2015)
Long-Term Efficacy of Systemic Multiexon Skipping Targeting Dystrophin Exons 45-55 With a Cocktail of Vivo-Morpholinos in Mdx52 Mice
Yusuke Echigoya et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2015)
The new frontier of genome engineering with CRISPR-Cas9
Jennifer A. Doudna et al.
SCIENCE (2014)
Understanding the Process of Fibrosis in Duchenne Muscular Dystrophy
Yacine Kharraz et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)
Stuart J. Moat et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2013)
Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice
Maaike van Putten et al.
FASEB JOURNAL (2013)
Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy
Jerry R. Mendell et al.
MUSCLE & NERVE (2013)
Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains
Maaike van Putten et al.
NEUROMUSCULAR DISORDERS (2012)
TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction
Erin L. Doyle et al.
NUCLEIC ACIDS RESEARCH (2012)
The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology
Maaike van Putten et al.
PLOS ONE (2012)
Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery
Yoshitsugu Aoki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
Sebahattin Cirak et al.
LANCET (2011)
Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription
Feng Zhang et al.
NATURE BIOTECHNOLOGY (2011)
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Nathalie M. Goemans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting
Tomas Cermak et al.
NUCLEIC ACIDS RESEARCH (2011)
Targeting Fibrosis in Duchenne Muscular Dystrophy
Lan Zhou et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2010)
Accurate quantification of dystrophin mRNA and exon skipping levels in Duchenne Muscular Dystrophy
Pietro Spitali et al.
LABORATORY INVESTIGATION (2010)
In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52-Deficient mdx Mouse
Yoshitsugu Aoki et al.
MOLECULAR THERAPY (2010)
Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations
Annemieke Aartsma-Rus et al.
HUMAN MUTATION (2009)
In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping
Hans A. Heemskerk et al.
JOURNAL OF GENE MEDICINE (2009)
Generation and characterization of transgenic mice with the full-length human DMD gene
Peter A. C. 't Hoen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Compositional analysis of muscle in boys with Duchenne muscular dystrophy using MR imaging
FA Marden et al.
SKELETAL RADIOLOGY (2005)
Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy
A Aartsma-Rus et al.
NEUROMUSCULAR DISORDERS (2002)
Three mouse models of muscular dystrophy:: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin α2-deficient mice
AM Connolly et al.
NEUROMUSCULAR DISORDERS (2001)
Share Paper
